FDA has accepted Kowa’s NDA for NCX 470 and set an April 30, 2027 PDUFA date after two Phase 3 trials established noninferiority to latanoprost in lowering intraocular pressure.
Bausch + Lomb is dropping BL1107 eye drops after a Phase 2 glaucoma miss and redirecting the asset toward a geographic atrophy implant.
Eylea is under pressure. Bayer’s $2.45bn Perfuse bet tests whether PER-001 can carry its next ophthalmology growth story.
Retinal disease care still targets drivers. Spinogenix is testing whether synaptic regeneration can protect vision when damage continues.
Lupin has completed its VISUfarma acquisition. Read what the deal changes for European ophthalmology, specialty pharma growth, and execution risk.
Nanodropper’s glaucoma study suggests microdrops may improve pressure control and reduce waste. Read what this could mean for eye care.